04.08.2009 10:00:00

UCB Selects Genpact to Manage its Global Finance & Accounting Operations

Genpact (NYSE:G), a leader in the globalization of services and technology and a pioneer in managing business processes for companies around the world, today announced it has been awarded a five-year contract to provide multiple finance and accounting (F&A) services to UCB, a global biopharmaceuticals company. Through this new partnership, Genpact will deploy experts at its near-shore location in Romania, and additional centers in India, to increase the operational effectiveness of UCB’s F&A systems across eleven European countries and the United States.

Commenting on the importance of this new relationship, Olaf Elbracht, Vice President Accounting, Reporting & Shared Services at UCB said, "Genpact’s proven track record of maximizing efficiency in F&A processes was a major factor in our decision to select them as our partner for this critical initiative. We believe that Genpact’s pharmaceutical industry expertise, ability to deliver F&A services from ‘near-shore’ locations and its reputation for streamlining complex business processes, makes it well-suited to support UCB.”

Genpact provides finance and accounting services to over three dozen global enterprises, including several of the largest pharmaceutical companies in the world. The company will support UCB in the areas of accounts payable, expense claims processing, fixed assets accounting, general accounting and procurement as well as select accounts receivable activities.

"We are delighted to be applying our domain expertise and skills in F&A and look forward to a long partnership with UCB,” said Genpact President & CEO Pramod Bhasin. "Our granular process knowledge, deep insights from handling over 3,000 business processes and global best practices, allow us to focus on driving effectiveness in core business processes leading to significant business outcomes for our clients. With tools like Lean and Six Sigma to help reduce costs increase productivity and improve quality, we believe we will be able contribute substantially to improving the effectiveness of UCB’s F&A operations.”

About Genpact

Genpact (NYSE:G) is a leader in the globalization of services and technology and a pioneer in managing business processes for companies around the world. The company combines process expertise, information technology and analytical capabilities with operational insight and experience in diverse industries to provide a wide range of services using its global delivery platform. Genpact helps companies improve the ways in which they do business by applying Six Sigma and Lean principles plus technology to continuously improve their business processes. Genpact operates service delivery centers in China, Guatemala, Hungary, India, Mexico, Morocco, the Netherlands, the Philippines, Poland, Romania, Spain and the United States. For more information, see our website at: www.genpact.com.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing about 10, 000 people in over 40 countries, UCB achieved revenues of 3.6 billion Euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Gillette Co.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Gillette Co.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

S&P 500 5 970,84 -1,11%
S&P 100 2 940,20 -1,22%